NIKKEI 225
27,362.75 -32.26 (-0.12%) HANG SENG
22,566.78 +522.13 (+2.37%) CRUDE OIL
81.10 +0.95 (+1.19%) GOLD FUTURES
1,929.70 -12.90 (-0.66%) DOW
33,949.41 +205.57 (+0.61%) BTC-GBP
18,603.89 -410.40 (-2.16%)
ABIONYX Pharma SA (0RAG.L)
- Business Wire
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
TOULOUSE, France & LAKELAND, Mich., January 16, 2023--ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI) met its primary objective. There are no approved treatments for septic patie
- Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2023
TOULOUSE, France & LAKELAND, Mich., January 13, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.
- Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, January 04, 2023--Regulatory News: ABIONYX Pharma (Paris:ABNX):
